Congress demands transparency on drug-plan middlemen's hidden deals
S. 3729 — PBM Reporting Transparency Act · Filed by Mark Warner (D-VA) · 3 cosponsors · Introduced Jan 29, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare's Payment Advisory Commission (MedPAC) to study and report to Congress on the agreements between pharmacy benefit managers (PBMs) and Medicare drug plans, examining trends, cost impacts on patients, and pharmacy reimbursement rates. The first report is due roughly 2 years after data becomes available; a follow-up report tracking changes is due 2 years later.
Why we flagged it
The bill's sole operative mechanism is a reporting requirement — it does not regulate PBMs, cap fees, or change payment rules. Its function is to illuminate currently opaque agreements so Congress can make informed policy decisions.
What the text implies
- Report findings may trigger follow-on legislation to regulate PBM practices, claw back rebates, or restructure drug-plan contracting — the transparency itself is a precursor to potential enforcement.
- PBMs may alter or obscure agreement terms in anticipation of reporting, or lobby to narrow the scope of data MedPAC can access before the first report deadline.
The full analysis lists 3 implications of this text.
Who it affects
Ordinary Medicare beneficiaries and the public gain transparency into PBM practices that directly affect their out-of-pocket drug costs and pharmacy access. Congress obtains data to evaluate whether regulatory or contractual reforms are needed, shifting power from opaque private intermediaries toward democratic oversight.